Evaluation of the clinical application of histamine H2 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting based on the attribute hierarchy model method

H2 RAs remain widely used in the prevention of CINV; however, the majority of cases (98.45%) demonstrated irrational use, particularly prophylactic administration without appropriate indications. The rationality of H2 RAs use in oncology departments was lower than that in non-oncology departments, while the associated drug costs were higher. Strengthened management of H2 RAs application in CINV prevention is needed to improve the rationality of drug use and to ensure safety, efficacy, and cost-effectiveness for patients.